Do GLP-1 drugs like semaglutide slow aging?

Background

GLP-1 medicines such as semaglutide and tirzepatide are approved for diabetes and weight management. Because they reduce several age-related diseases, some researchers have asked whether they act on aging itself.

What the human research shows

• The SELECT trial (17,604 adults with overweight or obesity and existing heart disease, without diabetes) found semaglutide reduced major cardiovascular events by about 20%.
• A follow-up analysis of SELECT also reported fewer deaths from any cause in the semaglutide group.
• Benefits on heart, kidney and liver disease are being tested and approved disease by disease.

What we still don’t know

• Whether these drugs slow biological aging itself, rather than treating specific diseases.
• Effects in lean, healthy people, who have not been studied for this purpose.
• The long-term effects of losing muscle along with fat.

Safety and status

Prescription drugs with real side effects, including gastrointestinal problems and, rarely, pancreatitis and gallbladder disease. Compounded and online “research” versions are not the approved products.

Sources

1. ACC summary: SELECT, semaglutide vs. placebo in people with overweight or obesity and heart disease (NEJM, 2023)
2. The effect of semaglutide on mortality: an analysis from the SELECT trial (2024)
3. VALREXA profile: Semaglutide
4. VALREXA profile: Tirzepatide

Last reviewed November 7, 2026. Educational only; not medical advice, and not a recommendation to take any drug or supplement. Talk to a clinician before starting anything.